Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Pharma Head Tapped to Replace Oxford GlycoSciences CEO

NEW YORK, May 24 - Oxford GlycoSciences today said it has hired David Ebsworth to take over the CEO post after Michael Kranda leaves on July 11.


Ebsworth, 47, will be "CEO Designate" and formally begin on July 1, according to OGS. He will work alongside Kranda, who cited family reasons for his departure.

 

The new CEO comes to OGS from Bayer, where he ran its worldwide pharmaceutical business. Before that he was president of the German giant's North American pharmaceutical division.

 

Click here for more information.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.